



March 8, 2018, 8.27 a.m.

## Ad hoc Release

### **STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share**

Bad Vilbel, March 8, 2018 – The Executive Board and Supervisory Board of STADA Arzneimittel AG (STADA) resolved today to propose to the General Meeting of STADA on June 6, 2018 the payment of a dividend in the amount of €0.11 per STADA share and to carry forward the remaining profits in the amount of €54m to new account. Thus, the dividend will be significantly lower than in previous years. In order to withstand the competition in the pharmaceuticals market, STADA must be able to invest in R&D, new products, technologies and markets. Therefore, the Executive Board and Supervisory Board consider it necessary to strengthen the company's equity capital. The Executive Board expressly points out that the proposed appropriation of profits is subject to approval by the General Meeting.

As planned, STADA will today, on March 8, 2018 publish its annual financial statements as well as the consolidated annual financial statements for the 2017 financial year.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [leslie.iltgen@stada.de](mailto:leslie.iltgen@stada.de)

Or visit us in the Internet at [www.stada.com](http://www.stada.com).

Executive Board: Dr. Claudio Albrecht (Chairman) / Mark Keatley / Dr. Barthold Piening  
Chairman of the Supervisory Board: Dr. Günter von Au